Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Journal of Hepatocellular Carcinoma|March 11, 2024
Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion ChemotherapyWenxuan Li, Zhikai Zheng, Jiongliang Wang, et al.
Liver Cancer|April 17, 2026
Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World StudyRui Xiao, Zhenyun Yang, Zehao Zheng, et al.
Immunotargets and Therapy|October 31, 2024
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular CarcinomaXiang Tang, Jinbin Chen, Wei Peng, et al.
The International Journal of Biological Markers|February 8, 2020
Long non-coding RNA <i>AGER-1</i> inhibits colorectal cancer progression through sponging miR-182Mingzhu Lin, Yinyan Li, Jianfeng Xian, et al.
Frontiers in Immunology|June 27, 2025
PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacyFei Cao, Chunyong Wen, Yujia Wang, et al.
Journal of Inflammation Research|October 14, 2022
Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic CholangiocarcinomaZhenyun Yang, Deyao Zhang, Huilan Zeng, et al.
Therapeutic Advances in Gastroenterology|April 22, 2024
The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysisWei Peng, Yangxun Pan, Lan Xie, et al.
Journal of Gastroenterology|March 9, 2023
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosisYizhen Fu, Wei Peng, Weixiang Zhang, et al.
Journal of Hepatocellular Carcinoma|June 1, 2026
HAIC Combined with Lenvatinib and Pembrolizumab for Unresectable Hepatocellular Carcinoma: A Retrospective StudyJun Liang, Zhenyun Yang, Zhuolin Yang, et al.
International Journal of Cancer|January 21, 2025
Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world studyMinrui He, Wa Xie, Ze Yuan, et al.
Pageof 9